Oberprieler NG, Pladevall-Vila M, Johannes C, Layton JB, Golozar A, Lavallee M, Liu F, Kubin M, Vizcaya D. FOUNTAIN: a modular research platform for integrated real-world evidence generation. BMC Med Res Methodol. 2024 Oct 1;24(1):224. doi: 10.1186/s12874-024-02344-w
Parikh R, Hess LM, Esterberg E, Bhandari NR, Kaye JA. Diagnostic characteristics, treatment patterns, and clinical outcomes for US patients with advanced/metastatic medullary thyroid cancer: a retrospective medical record review. J Thyroid Res. 2022;15(2). doi: 10.1186/s13044-021-00119-9
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Pajouheshnia R, Peelen LM, Moons KGM, Reitsma JB, Groenwold RHH. Accounting for treatment use when validating a prognostic model: a simulation study. BMC Med Res Methodol. 2017 Jul 14;17(1):103. doi: 10.1186/s12874-017-0375-8
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Pajouheshnia R, Pestman WR, Teerenstra S, Groenwold RHH. A computational approach to compare regression modelling strategies in prediction research. BMC Med Res Methodol. 2016 Aug 25;16(1):107. doi: 10.1186/s12874-016-0209-0
Le HV, Poole C, Brookhart MA, Schoenbach VJ, Beach KJ, Layton JB, Stumer T. Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example. BMC Med Res Methodol. 2013 Nov 19;13:142. doi: 10.1186/1471-2288-13-142
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, Solomon DH, Kim SY, Rothman KJ, Avorn J. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012 Nov 26;12(11):180.
Gili M, Luciano JV, Bauzá N, Aguado J, Serrano MJ, Armengol S, Roca M. Psychometric properties of the IDS-SR30 for the assessment of depressive symptoms in Spanish population. BMC Med Res Methodol. 2011 Sep;21(11):131.
Luciano JV, Ayuso-Mateos JL, Aguado J, Fernandez A, Serrano-Blanco A, Roca M, Haro JM. The 12-item World Health Organization Disability Assessment Schedule II (WHO-DAS II): a nonparametric item response analysis. BMC Med Res Methodol. 2010 May 20;10(45). doi: 10.1186/1471-2288-10-45.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Cann CI, Fried MP, Rothman KJ. Epidemiology of squamous-cell cancer of the head and neck. Otolaryngol Clin N Am. 1985 Aug 1;18(3):367-88.